Thunderbolt is a computer‑assisted vacuum thrombectomy (CAVT) device indicated for the treatment of acute ischaemic stroke.
Developed by thrombectomy company Penumbra, Thunderbolt is the first system in the company’s neuro thrombectomy portfolio to incorporate modulated aspiration technology.
Recommended Buyers Guides
The Thunderbolt CAVT system obtained regulatory clearance from the US Food and Drug Administration (FDA) and was granted CE marking in Europe in June 2026, making it the first and only device to achieve the approvals.
Design and features of Thunderbolt CAVT system
The Thunderbolt CAVT system’s main components are distal aspiration tubing, proximal aspiration tubing, a saline spike, a suction connector, a Thunderbolt control panel and a USB power adapter.
The system is powered by the Penumbra ENGINE® revascularisation device, which is designed to deliver and sustain a near‑pure vacuum of approximately ‑29.2 inches of mercury (98.9 kilopascals). The Penumbra ENGINE features an integrated clot catcher and a disposable canister.
The Thunderbolt CAVT uses pressure differentials and flow‑based algorithms to support clot detection at the catheter tip and is designed to identify, weaken and fully remove clot material at the site of vessel occlusion.
The device’s modulated aspiration capability is engineered to fatigue clot material at a rate of up to 12 pulses per second.
The device is supplied pre‑packaged with one catheter from Penumbra’s existing range, which may include Red 62, Red 68, Red 72 Silver Label, or Red 72 Silver Label incorporating SENDit technology, which is a unique tapered obturator that is used instead of a microcatheter.
RED catheter technology
Penumbra’s RED reperfusion catheters are intended for revascularisation in patients with acute ischaemic stroke, offering a range of diameters configured for use in different vessel segments on a case‑by‑case basis.
Thunderbolt is advised for use in conjunction with the BMX®81 access system when used with the Red 62 catheter, or with the BMX96® access system when used with the broader Penumbra catheter portfolio.
Clinical studies of Thunderbolt CAVT
In July 2026, Penumbra launched the FORWARD study, an international, real‑world, prospective, multicentre investigation designed to collect safety and efficacy data on mechanical thrombectomy – including CAVT and modulated aspiration – for the treatment of acute ischaemic stroke with distal vessel occlusions.
FORWARD (Functional Outcomes in Real‑World Treatment and Revascularization of Non‑dominant and Distal M2 Occlusions) is set to enrol up to 250 patients across approximately 40 sites.
The study aims to assess the performance of Penumbra’s RED reperfusion catheter portfolio, including Thunderbolt, to apply modulated aspiration in the treatment of acute ischaemic stroke in M2 occlusions.
Thunderbolt CAVT system benefits
Penumbra’s Thunderbolt CAVT platform is designed to enhance procedural efficiency and support wider use of minimally invasive clot‑removal techniques in acute ischaemic stroke cases. In Europe and the US, it is currently the only CAVT device available for use in stroke care.
Stroke ranks as the world’s second most common cause of death. Where a clot is not completely cleared, patients face a higher likelihood of major complications, long-term disability or fatal outcomes. A recent assessment suggests global deaths due to stroke could rise by around 50% from 2020 to 2050.
The system is intended to help reduce thrombectomy procedure times, a key consideration in stroke care, where treatment delays are associated with ongoing loss of brain tissue. It is also designed to enhance patient safety, improve clinical results and make workflows more efficient for the clinicians providing treatment.
The Thunderbolt CAVT platform adds to Penumbra’s existing CAVT platforms, which include Lightning Bolt® 12 and Lightning Bolt 6X with TraX™.
